Nachrichten zur Abbvie Inc. Aktie

AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine

ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.…

Johnson & Johnson Hopes to Dethrone AbbVies Biggest Growth Driver. Heres Why Investors Shouldnt Panic

AbbVies shareholders can sleep easy.…

CytomX (CTMX) Q4 2025 Earnings Transcript

Image source: The Motley Fool.DATEMonday, Mar. 16, 2026 at 8 a.m. ETCALL PARTICIPANTSChief Executive Officer and Chairman — Sean McCarthy,…

The S&P 500 Is Expensive, but These 3 Dividend Stocks Still Look Like Bargains

AbbVie, CVS Health, and Verizon Communications are all high-yielding stocks with attractive valuations and robust financials.…

CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics

NASDAQ: ATOSDavid Bautz, PhD: Welcome to the next episode of our CEO Chat series. My name is David Bautz, and…

AbbVie Inc. (ABBV) Presents at EU Clinical Trial Regulation: Latest Developments and Upcoming Opportunities Transcript

…

AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue?

AbbVie (ABBV) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

How Did AbbVies Oncology Portfolio Perform in Q1 Despite Headwinds?

ABBVs oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.…

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock…

Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set…

How Important Are Skyrizi and Rinvoq to AbbVies Q1 Results?

ABBVs Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.…

AbbVie Inc. (ABBV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

…

Top Stock Reports for NVIDIA, Mastercard & AbbVie

NVIDIA, Mastercard and AbbVie headline Zacks top stock reports, with AI growth, payment trends and drug launches in focus.…

AbbVie Deserves A Higher Multiple

…

CHRS Q1 2026 Earnings Transcript

Image source: The Motley Fool.DATEMonday, May 11, 2026 at 5 p.m. ETCALL PARTICIPANTSChief Executive Officer — Dennis M. LanfearChief Medical…

AbbVies Latest Results Reveal a Trend Investors Shouldnt Overlook

But is the stock a buy on the dip?…

Evolus (EOLS) Q2 2025 Earnings Call Transcript

Image source: The Motley Fool.DATETuesday, August 5, 2025 at 4:30 p.m. ETCALL PARTICIPANTSPresident & Chief Executive Officer — David MoatazediChief…

US FDA declines to approve AbbVie’s wrinkle treatment due to manufacturing concerns (April 23)

US FDA declines to approve AbbVie’s wrinkle treatment due to manufacturing concerns (April 23)…

AbbVie’s Earnings Beat Wall Street’s Estimates. Investors Are Still Worried

…

AbbVie upgraded to ‘Buy’ as growth outlook strengthens despite competition fears

AbbVie upgraded to ‘Buy’ as growth outlook strengthens despite competition fears…

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie on Wednesday reported better-than-expected quarterly revenue and profit, fueled by demand for newer immunology drugs Skyrizi and Rinvoq, as…

ABBV Beats on Q1 Earnings & Sales, Raises 26 EPS View

AbbVie tops Q1 estimates on strong Rinvoq and Skyrizi sales, lifts 2026 EPS outlook and gains premarket despite continued Humira…

AbbVies TrenibotE Receives FDA CRL Due to Manufacturing Issues

ABBV gets FDA CRL for TrenibotE tied to manufacturing issues. The company plans a full response in the coming months.…

US FDA rejects AbbVie’s wrinkle treatment due to manufacturing concerns

US FDA rejects AbbVie’s wrinkle treatment due to manufacturing concerns…

AbbVie to build $1.4B North Carolina plant

AbbVie to build $1.4B North Carolina plant…

AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock

AbbVie stock trades below key SMAs, signaling weakness, but strong Skyrizi and Rinvoq growth and a robust pipeline could support…

Thyroid Eye Disease Treatment Market Research Report 2026 Featuring Amgen, Viridian, Novartis, Roche, Sanofi, AbbVie, and Teva with Analyst Recommendations and Forecasts to 2031

Market opportunities in the Thyroid Eye Disease Treatment sector include advancements in therapeutic approaches, rising awareness, improved diagnostics, and expanded…

AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw AbbVie (ABBV) settling at $210.26, representing a +1.84% change from its previous close.…

Could AbbVie Crash Lillys Weight?Loss Party?

AbbVie is making progress in this market, but it is still far behind the leader.…

AbbVie ovarian cancer drug shows 62.7% response rate in trial

AbbVie ovarian cancer drug shows 62.7% response rate in trial…

AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note

In the most recent trading session, AbbVie (ABBV) closed at $206.69, indicating a -1.03% shift from the previous trading day.…

AbbVie: A High 2026 Earnings Bar, But Shares Are Attractive On Valuation

…

AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) concluded the recent trading session at $213.12, signifying a +1.78% move from its prior days close.…

Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now

AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation.…

AbbVie (ABBV) Declines More Than Market: Some Information for Investors

AbbVie (ABBV) reached $206.23 at the closing of the latest trading day, reflecting a -1.01% change compared to its last…

AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?

AbbVie slips below its 50-day SMA, signaling short-term weakness, but strong drug growth and a solid long-term uptrend may keep…

OTC Markets Hosts Virtual Investor Presentation with Dr. Seth Lederman, Co-Founder, CEO, and Chairman of Tonix Pharmaceuticals, and David Bautz, PhD, Senior Analyst at Zacks SCR

NASDAQ: TNXPJohn Viglotti: Hello, and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host,…

AbbVie (ABBV) Dips More Than Broader Market: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $219.68, moving 2.52% from the previous trading session.…

ROUNDUP: Botox und Co. - Minimalinvasive Eingriffe immer gefragter

BERLIN (dpa-AFX) - Immer mehr Menschen lassen minimalinvasive Eingriffe beim Schönheitschirurgen durchführen. Zu minimalinvasiven Eingriffen gehören…

Elahere (AbbVie: mirvetuximab soravtansine-gynx) Market Research Report 2026: Epidemiology, Competitive Landscape, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Opportunities in the Elahere market include the rising incidence of ovarian cancer, increased precision oncology adoption, FR alpha-targeted treatments, and…

AbbVie (ABBV) Up 6.1% Since Last Earnings Report: Can It Continue?

AbbVie (ABBV) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights

In the most recent trading session, AbbVie (ABBV) closed at $232.35, indicating a -1.63% shift from the previous trading day.…

Arcturus (ARCT) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DATETuesday, March 3, 2026, at 4:30 p.m. ETCALL PARTICIPANTSPresident and CEO — Joseph E. PayneChief Medical…

Evolus (EOLS) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DateTuesday, March 3, 2026 at 4:30 p.m. ETCall participantsPresident and Chief Executive Officer — David MoatazediChief…

Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now?

AbbVie (NYSE:ABBV) is one of the best cancer stocks to invest in now. On February 23, AbbVie (NYSE: ABBV) announced…

AbbVie makes $380 million made in the U.S. move

The Chicago-based biopharmaceutical company AbbVie made a significant move on Feb. 23, as part of its broader commitment to invest…

AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its…

AbbVie investing $380M on two new plants in North Chicago, adding 300 employees

AbbVie is doubling down on its drug manufacturing expansion at its North Chicago campus by building two facilities to support…

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities…

Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs

JNJs diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with…